All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): K102
Therapeutic Area: Neurology Product Name: K102
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Amneal Pharmaceuticals
Deal Size: $108.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 12, 2021
Details:
The acquisition enhances Amneal's R&D expertise with the addition of the Kashiv Specialty team and its impressive track record in developing complex generic products (e.g. Yuvafem and EluRyng) and innovative drug delivery technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydroxylated Sulfamides derivatives
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Neuropathix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2020
Details:
Neuropathix has acquired novel hydroxylated sulfamides from Advanced Neural Dynamics and Fox Chase Chemical Diversity Center. These acquisitions provide Neuropathix another exciting avenue for strong clinical pipelines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Topiramate
Therapeutic Area: Neurology Product Name: ET-101
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in patients, two years old.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CRISPR based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biogen
Deal Size: $415.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration October 06, 2020
Details:
Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 17, 2020
Details:
Following initial efforts focused on multiple sclerosis (MS), PicnicHealth, Roche and Genentech recently expanded their collaboration to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opioid based transdermal medications
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Nutriband
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 16, 2020
Details:
With this acquisition Pocono plans to consolidate capabilities at both facilities to expand on enhancing revenue stream opportunities and in-house product development, specifically our abuse deterrent technology for opioid based transdermal medications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Undisclosed Upfront Cash: $72.5 million
Deal Type: Collaboration June 23, 2020
Details:
Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: Precedex
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020
Details:
Vizient has signed an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ENX-101
Therapeutic Area: Neurology Product Name: ENX-101
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Nan Fung Life Sciences
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2020
Details:
The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Neurology Product Name: Trappsol Cyclo
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
The final report to FDA states that the drug showed a favorable safety profile as well as encouraging observations of benefit. Safety was monitored by MRIs, ECGs, laboratory safety assessments, and adverse events, all of which supported a favorable safety profile.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
